CDH1 and breast carcinoma: One such MEK inhibitor, PD0325901 (mirdametinib), can revert the hyper-proliferative phenotype induced by E-cad expression, both in vitro and in vivo, in various subtypes of IDC, including triple negative breast cancer (TNBC) and hormone receptor-positive (HR+) breast cancer [7].